Cannabis for cancer related pain and risk of harms and adverse events
The Cancer Pain Subgroup’s latest guideline looks at cannabis for cancer related pain, as well as the risk of harms. Based on the evidence, the authors recommend against the use of cannabinoids as an adjuvant analgesic for cancer pain and suggests that the potential risk of harm and adverse events be carefully considered for all cancer patients, particularly with treatment with a checkpoint inhibitor.
Read the full guideline or download a summary
Prevention and management of acute radiation dermatitis
The Oncodermatology Study Group has recently published a guideline examining the prevention and management of acute radiation dermatitis (ARD). A four-round Delphi consensus process was used, and led to the recommendation of six interventions for the prevention of ARD: photobiomodulation therapy and Mepitel film in people with breast cancer, Hydrofilm, mometasone, betamethasone, and olive oil. As well, Mepilex Lite dressings were recommended for ARD management.
Read the full guideline or download a summary
Endorsed Guideline: Prevention of acute and delayed chemotherapy-induced nausea and vomiting in pediatric cancer patients
This external guideline was recently endorsed by the Pediatrics Study Group. From the abstract:
“This clinical practice guideline provides recommendations for preventing acute and delayed phase chemotherapy-induced nausea and vomiting (CINV) in pediatric patients. The recommendations are based on two systematic reviews of randomized controlled trials evaluating interventions to prevent (1) acute phase CINV and (2) delayed phase CINV. Recommendations for acute phase and delayed phase CINV prophylaxis are made for patients receiving chemotherapy of varying emetogenicity, as well as for patients not able to receive dexamethasone or a neurokinin-1 receptor antagonist. Evidence gaps, including antiemetic safety and optimal dosing, were identified.”
